Albireo Pharma, Inc. (ALBO)
| Market Cap | 563.94M |
| Revenue (ttm) | 8.73M |
| Net Income (ttm) | -119.88M |
| Shares Out | 19.13M |
| EPS (ttm) | -6.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $29.31 |
| Previous Close | $29.38 |
| Change ($) | -0.07 |
| Change (%) | -0.24% |
| Day's Open | 29.57 |
| Day's Range | 28.60 - 30.25 |
| Day's Volume | 208,552 |
| 52-Week Range | 22.78 - 49.00 |
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial...
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-syste...
– First approval in the world of Bylvay for the treatment of PFIC –
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...
Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data will be...
– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –
– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) –
– Data being presented show long-term benefits of Bylvay in children with PFIC –
ALBO, EBMT, GAN, IRTC, and WLKP have been added to the Zacks Rank #5 (Strong Sell) List on May 26, 2021
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Exe...
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for the tr...
– Bylvay has the potential to become first approved drug to treat all forms of PFIC –
ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021
- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC -
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement s...
ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of -33.14% and -25.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–
Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the up...
– Dosed first patients in Phase 1 study with new product candidate A3907 –
– Calls to unite global communities affected by rare diseases –
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation ...
Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...
– Company outlining large global rare cholestatic liver disease opportunity –
Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) i...
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advocat...
BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virt...
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of...
- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -
- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -
- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -
- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-
Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases Albireo stands together with the PFIC community to h...
BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of...
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the prici...
BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it h...
Albireo Pharma (ALBO) is in the news Tuesday after positive results from a recent clinical trial sent ALBO stock soaring higher. The post Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today appeare...
The company reported positive data from a clinical trial.
-Highly statistically significant reductions in both pruritus and serum bile acids-
— Conference call and webcast to be held at 8:30 a.m. EDT — — Conference call and webcast to be held at 8:30 a.m. EDT —
About ALBO
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also d... [Read more...]
| Industry Biotechnology | |
| CEO Ronald Cooper | Employees 90 |
| Stock Exchange NASDAQ | Ticker Symbol ALBO |
Financial Performance
In 2020, Albireo Pharma's revenue was $8.31 million, a decrease of -13.78% compared to the previous year's $9.64 million. Losses were -$107.63 million, 71.6% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 73.43, which is an increase of 150.53% from the latest price.